| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Fosgonimeton | NDX-1017; ATH-1017; ATH 1017 | Phase 3 Clinical | M3 Biotechnology | Alzheimer Disease; Dementia; Lewy Body Disease; Parkinson Disease | 詳細 |
| RGL-2102 | RGL-2102; RGL2102 | Phase 3 Clinical | Shanghai Regenelead Therapies Co Ltd | Diabetic Foot; Ischemia; Ulcer; Wound Infection | 詳細 |
| Ficlatuzumab | AV-299; SCH-900105 | Phase 3 Clinical | Aveo | Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colonic Neoplasms; Glioblastoma; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphoma; Multiple Myeloma; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Respiratory Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | 詳細 |
| Umikibart | YYB-101; NOV-1105; CLM-101 | Phase 2 Clinical | YooYoung Pharmaceutical Co Ltd | Colorectal Neoplasms; Solid tumours | 詳細 |
| ATH-1020 | ATH-1020 | Phase 1 Clinical | Athira Pharma Inc | Nerve Degeneration | 詳細 |
| ATH-1105 | ATH-1105 | Phase 1 Clinical | Athira Pharma Inc | Amyotrophic Lateral Sclerosis; Frontotemporal Dementia | 詳細 |
| Microbiome-optimized autologous stem cell therapy (Biotech Holdings) | Clinical | Biotech Holdings | Peripheral Vascular Diseases | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beperminogene perplasmid | AMG-0001-01; AMG-0001; DS-992; TREAT-HGF | Approved | Anges Mg, Osaka University | Collategene | Japan | Peripheral Arterial Disease; Ischemia | Anges Inc, null | 2019-03-01 | Arterial Occlusive Diseases; Atherosclerosis; Foot Ulcer; Ischemia; Peripheral Arterial Disease; Peripheral Vascular Diseases; Ulcer; Vascular Diseases | 詳細 |